Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: PRNAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
Alterity Therapeutics Limited filed a Form 6-K highlighting a scientific milestone for its lead drug candidate ATH434. Daniel Claassen, M.D., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will present late-breaking clinical data at the American Academy of Neurology Annual Meeting in Chicago.
The oral presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” is scheduled for Tuesday, April 21, 2026 at 6:21 PM. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and additional positive data in an open-label Phase 2 trial in advanced disease.
Alterity is a clinical stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial in MSA. The company also maintains a broader discovery platform targeting underlying pathology in neurodegenerative diseases.
Alterity Therapeutics Limited filed a Form 6-K highlighting a scientific milestone for its lead drug candidate ATH434. Daniel Claassen, M.D., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will present late-breaking clinical data at the American Academy of Neurology Annual Meeting in Chicago.
The oral presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” is scheduled for Tuesday, April 21, 2026 at 6:21 PM. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and additional positive data in an open-label Phase 2 trial in advanced disease.
Alterity is a clinical stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial in MSA. The company also maintains a broader discovery platform targeting underlying pathology in neurodegenerative diseases.
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.
Alterity Therapeutics is hosting a virtual key opinion leader webcast to discuss ATH434 for treating Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment. The event will feature neurologists Roy Freeman, MD, and Daniel Claassen, MD, MS, alongside CEO David Stamler, MD.
The company describes ATH434 as its lead asset and notes that it has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data from an open label Phase 2 study in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader drug discovery platform targeting the underlying pathology of neurodegenerative diseases.
Alterity Therapeutics is hosting a virtual key opinion leader webcast to discuss ATH434 for treating Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment. The event will feature neurologists Roy Freeman, MD, and Daniel Claassen, MD, MS, alongside CEO David Stamler, MD.
The company describes ATH434 as its lead asset and notes that it has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data from an open label Phase 2 study in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader drug discovery platform targeting the underlying pathology of neurodegenerative diseases.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics Limited has filed a Form 6-K highlighting its planned participation in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia on 12-13 March 2026. CEO David Stamler, M.D. will join a fireside chat on optimising late-stage clinical trials and hold 1-on-1 investor meetings.
The company is a clinical-stage biotechnology business developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial and positive results in an open-label Phase 2 study, and the company is preparing a Phase 3 pivotal trial in MSA.
Alterity Therapeutics Limited has filed a Form 6-K highlighting its planned participation in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia on 12-13 March 2026. CEO David Stamler, M.D. will join a fireside chat on optimising late-stage clinical trials and hold 1-on-1 investor meetings.
The company is a clinical-stage biotechnology business developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial and positive results in an open-label Phase 2 study, and the company is preparing a Phase 3 pivotal trial in MSA.